Up next

Autoplay

Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks

0 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

http://cancerGRACE.org/

A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.

Show more
0 Comments sort Sort By

Up next

Autoplay